Research programme - pain therapeutics - Biogen/Evotec

Drug Profile

Research programme - pain therapeutics - Biogen/Evotec

Latest Information Update: 24 Jun 2015

Price : $50

At a glance

  • Originator Convergence Pharmaceuticals; Evotec AG
  • Developer Biogen; Evotec AG
  • Class Analgesics
  • Mechanism of Action G protein-coupled receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Pain

Most Recent Events

  • 31 Mar 2014 Convergence Pharmaceuticals and Evotec AG enters into research alliance for the development of pain therapeutics
  • 31 Mar 2014 Early research in Pain in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top